» Articles » PMID: 34995871

Systemic Inflammation and Risk of All-cause Mortality After Invasive Breast Cancer Diagnosis Among Hispanic and Non-Hispanic White Women from New Mexico

Overview
Publisher Elsevier
Specialties Oncology
Public Health
Date 2022 Jan 7
PMID 34995871
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Soluble tumor necrosis factor receptor-II (sTNF-R2), a pro-inflammatory biomarker, is associated with obesity and breast cancer (BC). The association between sTNF-R2 and risk of mortality after BC has not been studied, specifically among Hispanic women, an at-risk population due to their high prevalence of obesity and poor prognosis. We examined the association between sTNF-R2 and mortality among Hispanic and non-Hispanic white (NHW) BC survivors.

Methods: A total of 397 invasive BC survivors (96 Hispanic, 301 NHW) contributed baseline interview data and blood samples. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox proportional hazards regression models adjusting for clinical factors including body mass index.

Results: After a median follow-up time of 13 years, 133 deaths occurred. The association between high vs low levels of plasma sTNF-R2 and mortality was not statistically significant overall (HR, 1.32; 95% CI 0.89-1.98). However, when stratified the mortality risk among Hispanic women was nearly 3-fold (HR, 2.83; 95% CI 1.21-6.63), while risk among NHW women was attenuated (HR, 0.99; 95% CI 0.61-1.61) (p-interaction=0.10).

Conclusion: Our results suggest Hispanic BC survivors with high sTNF-R2 levels may have increased risk of mortality and could inform targeted interventions to reduce inflammation and improve outcomes.

Citing Articles

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.


Elevation of circulating TNF receptor 2 in cancer: A systematic meta-analysis for its potential as a diagnostic cancer biomarker.

Kartikasari A, Cassar E, Razqan M, Szydzik C, Huertas C, Mitchell A Front Immunol. 2022; 13:918254.

PMID: 36466914 PMC: 9708892. DOI: 10.3389/fimmu.2022.918254.

References
1.
Pierce B, Ballard-Barbash R, Bernstein L, Baumgartner R, Neuhouser M, Wener M . Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27(21):3437-44. PMC: 2717751. DOI: 10.1200/JCO.2008.18.9068. View

2.
Villasenor A, Flatt S, Marinac C, Natarajan L, Pierce J, Patterson R . Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomarkers Prev. 2013; 23(1):189-99. PMC: 3911892. DOI: 10.1158/1055-9965.EPI-13-0852. View

3.
Boone S, Baumgartner K, Joste N, Pinkston C, Yang D, Baumgartner R . The joint contribution of tumor phenotype and education to breast cancer survival disparity between Hispanic and non-Hispanic white women. Cancer Causes Control. 2013; 25(3):273-82. DOI: 10.1007/s10552-013-0329-3. View

4.
Baumgartner K, Hunt W, Baumgartner R, Crumley D, Gilliland F, McTiernan A . Association of body composition and weight history with breast cancer prognostic markers: divergent pattern for Hispanic and non-Hispanic White women. Am J Epidemiol. 2004; 160(11):1087-97. DOI: 10.1093/aje/kwh313. View

5.
Gross A, Newschaffer C, Hoffman-Bolton J, Rifai N, Visvanathan K . Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013; 22(7):1319-24. PMC: 4417498. DOI: 10.1158/1055-9965.EPI-12-1444. View